Encouraging News for Hepatitis C Vaccine
Share
Follow Us
First Vaccine for Viral Hepatitis C Could Become a Reality
Wednesday, April 06, 2011
Early data from phase I trials of an HCV vaccine presented at the International Liver Congress(TM) show encouraging results, with high immunogenicity and good safety profile.
BERLIN, GERMANY — In the first study¹, a therapeutic T-cell vaccine, based on novel adenoviral vectors was used on a small population of treatment naive patients with chronic genotype 1 HCV infection. Intra-muscular vaccination was administered 2 or 14 weeks into a 48-week course of treatment with Peg-IFNa2a/ribavirin. 50% of vaccinated patients had CD4+ and CD8+ HCV specific T-cell responses as detected by ELISpot at 2-8 weeks post boost, showing a strong immunogenicity for the vaccine. Local and systemic adverse events to vaccination were mild, with no evidence of liver immunopathology (measured by liver transaminase levels).
Continue reading this entire article:
http://www.mdnews.com/news/2011_04/first-vaccine-for-viral-hepatitis-c-could-become-a-reality
